 Neoplasm Proteins
"Neoplasm Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
| Descriptor ID |
D009363
|
| MeSH Number(s) |
D12.776.624
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Proteins".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Proteins".
This graph shows the total number of publications written about "Neoplasm Proteins" by people in this website by year, and whether "Neoplasm Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 | | 1996 | 5 | 3 | 8 | | 1997 | 2 | 0 | 2 | | 1998 | 4 | 3 | 7 | | 1999 | 1 | 0 | 1 | | 2000 | 7 | 4 | 11 | | 2001 | 8 | 5 | 13 | | 2002 | 2 | 8 | 10 | | 2003 | 7 | 6 | 13 | | 2004 | 8 | 4 | 12 | | 2005 | 7 | 4 | 11 | | 2006 | 9 | 2 | 11 | | 2007 | 5 | 7 | 12 | | 2008 | 7 | 4 | 11 | | 2009 | 10 | 4 | 14 | | 2010 | 8 | 0 | 8 | | 2011 | 5 | 3 | 8 | | 2012 | 5 | 10 | 15 | | 2013 | 10 | 7 | 17 | | 2014 | 9 | 3 | 12 | | 2015 | 8 | 4 | 12 | | 2016 | 9 | 6 | 15 | | 2017 | 11 | 4 | 15 | | 2018 | 10 | 7 | 17 | | 2019 | 10 | 3 | 13 | | 2020 | 9 | 6 | 15 | | 2021 | 8 | 2 | 10 | | 2022 | 1 | 1 | 2 | | 2023 | 0 | 2 | 2 | | 2024 | 2 | 4 | 6 | | 2025 | 4 | 1 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm Proteins" by people in Profiles.
-
Tiago M, Purwin TJ, Stefanski CD, da Silva RO, Fane ME, Chhabra Y, Haj JI, Teh JL, Kadamb R, Cai W, Rosenbaum SR, Chua V, Hacohen N, Davies MA, Villanueva J, Chervoneva I, Weeraratna AT, Erkes DA, Capparelli C, Aguirre-Ghiso JA, Aplin AE. Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma. J Clin Invest. 2025 Sep 16; 135(18).
-
Mokhonova EI, Helzer D, Malik R, Mamsa H, Walker J, Maslanka M, Fleser TS, Afsharinia MH, Liu S, Holmberg J, Zhou ZH, Deeds EJ, Hansen KC, McNally EM, Crosbie RH. Sarcospan protects against LGMD R5 via remodeling of the sarcoglycan complex composition in dystrophic mice. J Clin Invest. 2025 Sep 02; 135(17).
-
Singh K, Hotchkiss KM, Cook SL, Noldner P, Zhou Y, Moelker EM, Railton CO, Blandford EE, Puviindran BJ, Wallace SE, Norberg PK, Archer GE, Shaz BH, Ayasoufi K, Sampson JH, Khasraw M, Fecci PE. IL-7-mediated expansion of autologous lymphocytes increases CD8+ VLA-4 expression and accumulation in glioblastoma models. J Clin Invest. 2025 Jun 16; 135(12).
-
Shen Z, Wang Y, Gao J, Gu W, Ren Z, Xu L, Qian R, Miao Q, Hu X, Wu Y, Liu W, Cai Y, Wan CC, Zhu Y, Sun L, Yan T. The EZH2/MCM Complex/hTERT axis facilitates hepatocellular carcinoma progression by inhibiting cellular senescence. Mech Ageing Dev. 2025 Apr; 224:112040.
-
Key AM, Earley EJ, Tzounakas VL, Anastasiadi AT, Nemkov T, Stephenson D, Dzieciatkowska M, Reisz JA, Keele GR, Deng X, Stone M, Kleinman S, Hansen KC, Norris PJ, Busch MP, Roubinian NH, Page GP, D'Alessandro A. Red blood cell urate levels are linked to hemolysis in vitro and post-transfusion as a function of donor sex, population and genetic polymorphisms in SLC2A9 and ABCG2. Transfusion. 2025 Mar; 65(3):560-574.
-
Rodrigues Sousa E, de Brot S, Zoni E, Zeinali S, Brunello A, Scarpa M, De Menna M, La Manna F, Abey Alexander A, Klima I, Freeman DW, Gates BL, Cristaldi DA, Guenat OT, Kruithof BPT, Spike BT, Chouvardas P, Kruithof-de Julio M. CRIPTO's multifaceted role in driving aggressive prostate cancer unveiled by in vivo, organoid, and patient data. Oncogene. 2025 Mar; 44(7):462-475.
-
Lyu C, Vaddi PK, Elshafae S, Pradeep A, Ma D, Chen S. Unveiling RACK1: a key regulator of the PI3K/AKT pathway in prostate cancer development. Oncogene. 2025 Feb; 44(5):322-335.
-
Nielsen AJ, Albert GK, Sanchez A, Chen J, Liu J, Davalos AS, Geng D, Bradeen X, Hintzsche JD, Robinson W, McCarter M, Amato C, Tobin R, Couts K, Wilky BA, Davila E. DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors. J Clin Invest. 2024 Oct 22; 134(24).
-
Liu W, Cao H, Wang J, Elmusrati A, Han B, Chen W, Zhou P, Li X, Keysar S, Jimeno A, Wang CY. Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma. Nat Commun. 2024 Aug 08; 15(1):6755.
-
Zhu Y, Banerjee A, Xie P, Ivanov AA, Uddin A, Jiao Q, Chi JJ, Zeng L, Lee JY, Xue Y, Lu X, Cristofanilli M, Gradishar WJ, Henry CJ, Gillespie TW, Bhave MA, Kalinsky K, Fu H, Bahar I, Zhang B, Wan Y. Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers. J Clin Invest. 2024 Mar 26; 134(10).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|